Talk:Angiotensin II receptor blocker

message: ARB's have been shown to be teratogenic.
http://www.fda.gov/hearthealth/treatments/medications/arbs.html
under "pregnancy" category.
66.7.132.30 21:53, 27 August 2007 (UTC)
thread_title:  additional side effects 

message: The table comparing the drug pharmacokinetics needs looking at or referencing. Most of them are mostly excreted unchanged with little hepatic metabolism, or as I understand it from the MIMS database (database of drug information provided by manufacturer). The numbers aren't the wrong way around either, they're completely different.
On an additional note in regards to an earlier comment, 'Angiotensin II receptor antagonist' is the more correct term for the class of drug. 'Angiotensin receptor blocker' is a bit of a colloquialism like 'beta blocker', which should technically be 'beta-adrenergic receptor antagonist'.  —Preceding unsigned comment added by 58.168.42.137 (talk) 06:28, 7 April 2011 (UTC)
thread_title:  Comparison of Pharmacokinetics 

message: This addition is troubling. The cited meta-analysis found "(7.2%vs 6.0%, risk ratio [RR] 1.08, 95% CI 1.01-1.15; p=0.016)". A difference this small in a meta-analysis is nearly lost in the experimental error even if the methodology was perfect in all the original studies. Any flaws in methodology could wipe them out. But the real problem is that it looks at one particular endpoint (cancer) while ignoring others (whether stroke, cardiac events, or even lightning strike). The relevant comparison is for all types of M&M, not just one. On a random basis over the ensemble of outcomes, some risks appear to go up while others appear to go down. We can't tell if this RR is anything more than that random effect.LeadSongDog come howl! 13:46, 2 September 2011 (UTC)
thread_title:  Cancer risk 

message: I was moving from Wikipedia article to article trying to figure out what effects the different antihypertension drugs have (just the basic types, not specific drug names) and came across "These substances are AT1-receptor antagonists; that is, they block the activation of [angiotensin II AT1 receptors.]"  When I clicked the link, I was taken to a general article about all the angiotensin receptors and I had to remember that I was trying to figure out what a blocker of type 2 angiotensin would be doing to it.  It's easy to lose track of what you're trying to figure out, especially in a medical series of articles, and when the articles hand you a jargon and don't explain it right there.  Since I have to click through, maybe you could help me out with a handy script that pops up a sticky note saying "From angiotensin II blocker article.  Sentence:  These substances are AT1-receptor antagonists; that is, they block the activation of angiotensin II AT1 receptors. [Back to article]" Or put it at the top or bottom, or side of each page?  That would majorly help me keep it straight. Well consider it please. Thanks. -Confused  24.225.67.129 (talk) 14:16, 5 September 2013 (UTC)
thread_title:  Sticky note idea 

message: I noticed that Candesartan is not included in the any of the three bulleted lists on this page. 
Is there a reason for this, or can Candesartan be added by someone who knows the relevant figures/percentages?
Daveco333 (talk) 14:44, 20 July 2016 (UTC)
thread_title:  Should Candesartan be added to three bulleted lists? 

message: I mention this as a non-expert, not qualified to edit or add anything. A recent article says that "Antihypertensive medications that stimulate rather than inhibit type 2 and 4 angiotensin II receptors can lower the rate of dementia among new users of these medications, new research suggests".
, also doi:10.1001/jamanetworkopen.2022.49370  Without suggesting that this particular point needs to be addressed in advance of reviews, should Angiotensin II receptor stimulators not have an article? Maybe it already does, under another name?
Best wishes, Pol098 (talk) 18:09, 12 January 2023 (UTC)
thread_title:  Should angiotensin II receptor ''stimulators'' have an article?